(12) United States Patent (10) Patent No.: US 8,257,714 B2 Aylsworth Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US008257714B2 (12) United States Patent (10) Patent No.: US 8,257,714 B2 Aylsworth et al. (45) Date of Patent: Sep. 4, 2012 (54) COMPOSITIONS AND METHODS FOR 37. A &E SA i. al MMUNOTHERAPY OF CANCER AND 5,780,225 A 7/1998 Wiglertudnicka et al. et al. NFECTIOUS DISEASES 5,792,644 A 8/1998 Vermeulen et al. 5,807,715 A 9, 1998 Morrison et al. (75) Inventors: Charles Aylsworth, Holt, MI (US); 5,821,047 A 10/1998 Garrard et al. ill- 5,969,108 A 10/1999 McCafferty et al. SEEEMS)avid Juckett, East Lansing, MI (US); 6,008,3426,001,363 A 12/1999 TomleyBinger et etal al. John W. Judge, St. Johns, MI (US); 6,100,241 A 8, 2000 Kok et al. Barnett Rosenberg, Holt, MI (US); Igor 33. R 239, ably al y: Zlatkin, Millis,- - - - MA (US); Tatiana 6.451,984W B1 9/2002 Lillehoetalarter et al. Zlatkin, Millis, MA (US) 6,528,485 B1 3/2003 Veronese et al. (73) Assignee: Michigan State University, Lansing, MI FOREIGN PATENT DOCUMENTS (US) EP 239.400 A2 9, 1987 EP 519596 A1 12/1992 (*)c Notice:- r Subject to any disclaimer, the term of this WOEP WO 86,05807592106 A1 10,4f1994 1986 patent is extended or adjusted under 35 WO WO 89.01.036 A1 2, 1989 U.S.C. 154(b) by 793 days. WO WO90,02809 A1 3, 1990 WO WO 91.01134 A1 2, 1991 (21) Appl. No.: 12/102,292 WO WO91,09967 A1 7, 1991 9 WO WO91f10737 A1 7, 1991 WO WO91f10741 A1 7, 1991 (22) Filed: Apr. 14, 2008 WO WO92fO1047 A1 1/1992 WO WO92/04461 3, 1992 (65) Prior Publication Data WO WO92,06180 A1 4, 1992 WO WO92, 18619 A1 10, 1992 US 2009/O136999 A1 May 28, 2009 WO WO92/2O316 A2 11, 1992 WO WO92,22324 A1 12/1992 Related U.S. Application Data (Continued) (62) Division of application No. 10/892,659, filed on Jul. 15, 2004, now Pat. No. 7,393,534. OTHER PUBLICATIONS Wallach, et al. 1995 Vaccine 13(4): 347-354.* (60) Provisional application No. 60/487.336, filed on Jul. Merriam-Webster reference: www.merriam-Webster.com/dictionary/ 15, 2003. prevent; last accessed 2010 (2 pages total). Juckett D.A. et al., “Intestinal protozoa are hypothesized to stimulate (51) Int. C. immunosurveillance against colon cancer. Medical Hypotheses, A6 IK39/00 (2006.01) (2008) 71, 104-110. A 6LX39/002 (2006.01) Rader J.S. et al., “Phase I Study and Preliminary Pharmacology of the A6 IK35/68 (2006.01) Novel Innate Immune Modulator rBBX-01 in Gynecologic Cancers.” Clin. Cancer Res (2008): 14(10) 3089-3097. A6 IP3 L/16 (2006.01) Radar J.S. et al., “A Phase 1 Study of Bi-Weekly rBBX-01 in Patients (52) U.S. Cl. ............... 424/267.1; 424/271.1; 424/185.1; with Solid Tumors.” Version: Jan. 1, 2008; Feb. 3, 2008; Feb. 4, 2008/ 514/19.3: 514/2.3 Jun. 19, 2009; Aug. 4, 2008 per PRMC; pp. 1-47. (58) Field of Classification Search ........................ None See application file for complete search history. (Continued) Primary Examiner — Marsha Tsay (56) References Cited (74) Attorney, Agent, or Firm — Wolf, Greenfield & Sacks, P.C. U.S. PATENT DOCUMENTS 4,444,887 A 4, 1984 Hoffmann (57) ABSTRACT 4,716,111 A 12/1987 Osband et al. 4,816,397 A 3, 1989 BOSS et al. The present invention provides compositions and methods for 4,816,567 A 3/1989 Cabilly et al. the prevention and treatment of primary and metastatic neo 4,980,286 A 12/1990 Morgan et al. plastic diseases and infectious diseases, for stimulating an 5,122,464 A 6, 1992 Wilson et al. immune response in a Subject, and for use as an alternative to 5,223,409 A 6, 1993 Ladner et al. 5,225,539 A 7, 1993 Winter interleukin-12 (IL-12) treatment. In particular, the present 5,403.484 A 4/1995 Ladner et al. invention provides Apicomplexa-related proteins (ARPs) that 5,427,908 A 6, 1995 Dower et al. have immune stimulatory activity and thus have uses in the 5,436,146 A 7, 1995 Shenk et al. treatment and prevention of cancer and infectious diseases 5,516,637 A 5/1996 Huang et al. and in immune modulation. Compositions comprising an 5,530,101 A 6/1996 Queen et al. ARP are provided. Methods of use of an ARP for the preven 5,565,332 A 10/1996 Hoogenboom et al. tion and/or treatment of cancer and/or infectious diseases, for 5,571,698 A 11/1996 Ladner et al. 5,580,717 A 12/1996 Dower et al. use as an alternative to interleukin-12 (IL-12) treatment, and 5,585,089 A 12/1996 Queen et al. for eliciting an immune response in a subject, are also pro 5,658,727 A 8, 1997 Barbas et al. vided. 5,698,426 A 12, 1997 Huse 5,733,743 A 3, 1998 Johnson et al. 31 Claims, 38 Drawing Sheets US 8,257,714 B2 Page 2 FOREIGN PATENT DOCUMENTS Bout et al., 1994, "Lung Gene Therapy. In Vivo Adenvovirus-Medi WO WO92,22635 A1 12, 1992 ated Gene Transfer to Rhesus Monkey Airway Epithelium.” Human WO WO 93,11236 A1 6, 1993 Gene Therapy, 5: 3-10. WO WO 93.14188 A1 7, 1993 Brake, D.A., 2002. 'Vaccinology for control of apicomplexan para WO WO93/15199 A1 8, 1993 sites: a simplified language of immune programming and its use in WO WO93, 1520O A1 8, 1993 vaccine design.” IntJ Parasitol. 23(5): 509-15. WO WO93f2O221 A1 10, 1993 WO WO94,08598 A1 4f1994 Brightbill et al., 1999, "Host Defense Mechanisms Triggered by WO WO 94,12649 A1 6, 1994 Microbial Lipoproteins Through Toll-like Receptors.” Science WO WO93, 17105 A1 12, 1994 285(5428): 732-6. WO WO95/15982 A2 6, 1995 Brinkman et al., 1995, “Phage display of disulfide-stabilized Fv WO WO95/2O401 A1 8, 1995 fragments.” J. Immunol. Methods 182: 41-50. WO WO96,33735 A1 10, 1996 Buckheitet al., 1997, “Efficacy, Pharmacokinetics, and in Vivo Anti WO WO 96/34096 A1 10, 1996 viral Activity of UC781, a Highly Potent, Orally Bioavailable Non WO WO 97.13844 A1 4f1997 WO WO 98.24893 A2 6, 1998 nucleoside Reverse Transcriptase Inhibitor of HIV Type 1.” AIDS WO WO 98,46645 A2 10, 1998 Res. Hum. Retroviruses, 13: 789-796. WO WO 98.16654 A1 6, 1999 Burton et al., 1994, "Human Antibodies from Combinatorial Librar WO WO98,50433 A2 5, 2001 ies.” Advances in Immunology 57: 191-280. WO WO 2004/020643 3, 2004 Cabily et al., 1984. “Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli.” OTHER PUBLICATIONS Proc Natl AcadSci USA 81 (11): 3273-7. Ajioka, J. W. et al., 1998, "Gene Discovery by EST Sequencing in Cairns, J., 1975, "Mutation selection and the natural history of can Toxoplasma gondii Reveals Sequences Restricted to the cer, Nature, 255:197-200. Apicomplexa, Genome Research. Caldas et al., 2000, “Design and synthesis of germline-based hemi Aliberti, J. & Sher, A., 2002, “Role of G-protein-coupled signaling in humanized single-chain Fv against the CD18 Surface antigen.” Pro the induction and regulation of dendritic cell function by Toxoplasma tein Eng 13(5): 353-60. gondii,” Microbes and Infection 4: 991-997. Calman, K. 1974, “Why are small bowel tumors rare? An experimen Alibertietal., 2003, “Molecular mimicry of a CCR5 binding-domain tal model. Gut, 15:552-554. in the microbial activation of dendritic cells.” Nature Immunology Campos et al., 2001, “Activation of Toll-like Receptor-2 by 4(5): 485-490. Aliprantis A. et al., 1999, "Cell Activation and Apoptosis by Bacte Glycosylphosphatidy linositol Anchors from a Protozoan Parasite.” rial Lipoproteins through Toll-like Receptors-2.” Science 285:736 The J. Immunol. 167:416–423. 739. Carpenter, et al., 1998, “Antiretroviral Therapy for HIV infection in Allen & Fetterer, 2002, "Recent Advances in Biology and 1998.” JAMA 280(1): 78-86. Immunobiology of Eimeria Species and in Diagnosis and Control of Chan P. et al., 1975, "Small bowel extracts in the inhibition of tumour Infection with these Occidian Parasites of Poultry.” Clin. Microbic”. growth.” Gut, 16:50-52. Rev. 15:58-65. Chomczynsky, P. and Sacchi, N., 1987. “Single-Step Method RNA Almeida and Gazzinelli, 2001, “Proinflammatory activity of Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform glycosylphophatidylinositol anchors derived from Trypanosoma Extraction.” Anal. Biochem. 162:156-159. cruzi: structural and functional analyses.” J. Leukoc Biol. 70(4): 467 Chothia et al., 1998, "Structural Determinants in the Sequences of 77. Immunoglobulin Variable Domain.” J. Mol. Biol. 278: 457-479. Altschulet al., 1997 "Gapped BLAST and PSI-BLAST: a new gen Chou, P. and Fasman, G., 1974, "Prediction of Protein Conforma eration of protein database search programs. Nucleic Acids Res. tion.” Biochemistry vol. 13: No. 2, 222. 25(17): 3389-3402. Cline, 1985. “Perspectives for Gene Therapy: Inserting New Genetic Ames et al., 1995, “Conversion of murine Fabs isolated from a Informaiton into Mammalian Cells by Physical Techniques and Viral combinatoria phage display library to full length immunoglobulins.” Vectors. Pharmac. Ther. 29: 69-92. J. Immunol. Methods 184: 177-186. Clowes et al., 1994, "Long-Term Bilogical Response of Injured Rat Ashley S. & Wells S., 1988, “Tumors of the Small Intestine.” Semi Carotid Artery Seeded with Smooth Muscle Cells Expressing nars in Oncology, 15(2): 116-128. Retrovirally Introduced Human Genes,” J. Clin. Invest. 93: 644-651. Ausubel et al., 2002, “Informatics for Molecular Biologists.” Current Cockett et al., 1990, “High Level Expression of Tissue Inhibitor of Protocols in Molecular Biology, Ch.